Navigation Links
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Date:11/11/2009

Finland, November 11 /PRNewswire/ --

- This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009.

- FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

The pre-planned three-year interim analysis of a randomised, prospective trial (known as FinXX) compared adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for the treatment of early breast cancer with the standard, non-capecitabine regimen (docetaxel, epirubicin, cyclophosphamide and fluorouracil).[1] The analysis also found that patients taking the capecitabine-containing regimen were significantly less likely to have their cancer spread (distant metastasis) to another part of the body (a 36% reduction in risk was observed). This is the first phase III randomised trial to report efficacy of capecitabine combination therapy in the adjuvant treatment of early breast cancer.

"Capecitabine has already been shown to be effective in patients with advanced breast cancer. In addition, these results from the FinXX study show that using a capecitabine-containing regimen in the early stages of breast cancer may offer survival benefits for women, which is a primary goal of treatment," said Professor Heikki Joensuu, Principal Investigator, Helsinki University Hospital, Finland. "I am e
'/>"/>

SOURCE The Finnish Breast Cancer Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis
2. Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
5. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
6. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
7. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
8. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
9. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
10. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
11. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... 23, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ... integrated healthcare enterprise, today announced that the Group has accumulated ... Corporation ("CCBC," - CO.US) from the open market between December ... Group now owns 39.5% of the issued share capital of ...
... Four hospitals serving Virginia patients reduced healthcare-acquired infection rates ... in savings of $1.2 million in additional costs to ... plan to existing federal hand washing protocols, these hospitals ... and reduced patient length-of-stay and unnecessary readmissions. ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... 28, 2014 Dr. Andrew Campbell, one ... announced the expansion of Quintessa Aesthetic Center into a ... located at W307 N1497 Golf Road in Suite 200 ... Dr. Campbell, the new Delafield location will offer a ... patients, including: Botox, filler injectables , micro laser ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic surgeons ... for those in the area that would like to learn more ... will take place on December 11, 2014, from 6:00 p.m. until ... Houston at 4208 Richmond Ave. , “We want to wish ... and celebrate the season with us on December 11, 2014 from ...
(Date:11/28/2014)... Evergreen, Colorado (PRWEB) November 28, 2014 Written ... Jackson , Brook Forest Voices releases the “The Happiest ... audiobook , a compelling account of how and why Project ... of Idaho by his mother Josie and the Reverend Richard ... millionaire by the age of 30, but realized that he ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... , , WEDNESDAY, April 22 (HealthDay News) -- Responding to ... Administration said Wednesday that it will now allow 17-year-olds ... a doctor,s prescription. , In 2006, the FDA ... also known as Plan B, to women 18 and ...
... 22 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... New Jersey based company focused on clinical approval of ... disc replacement device. This strategic acquisition allows NuVasive the ...
... TMK ) reported today that for the quarter ... (after a charge of $.49 per share for impairment of ... quarter. Net operating income for the quarter was $1.49 ... per share for the year-ago quarter. Reconciliations between net income ...
... of drinking while pregnant, , , WEDNESDAY, April 22 (HealthDay ... and mental problems in babies born to women who ... known that drinking while pregnant can be harmful to ... to children with noticeable deficits, noted Chris Downing, a ...
... AMICAS, Inc. (Nasdaq: AMCS ), a ... solutions, today announced it will report the company,s financial ... after the market closes on Monday, May 11, 2009.(Logo: ... of its financial results, management will host a conference ...
... To Webcast Annual Shareholders MeetingLIONVILLE, Pa., April 22 ... announced today that it will release 2009 first quarter ... 30, 2009, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ...
Cached Medicine News:Health News:FDA Approves 'Plan B' Pill for 17-Year-Olds 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 2Health News:Torchmark Corporation Reports First Quarter 2009 Results 3Health News:Torchmark Corporation Reports First Quarter 2009 Results 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 5Health News:Torchmark Corporation Reports First Quarter 2009 Results 6Health News:Torchmark Corporation Reports First Quarter 2009 Results 7Health News:Torchmark Corporation Reports First Quarter 2009 Results 8Health News:Torchmark Corporation Reports First Quarter 2009 Results 9Health News:Torchmark Corporation Reports First Quarter 2009 Results 10Health News:Torchmark Corporation Reports First Quarter 2009 Results 11Health News:Torchmark Corporation Reports First Quarter 2009 Results 12Health News:AMICAS Schedules First Quarter 2009 Earnings Results Conference Call 2Health News:West to Host 2009 First Quarter Conference Call 2
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
... wide orifice tip, the Finntip Wide is ... and macromolecules like genomic DNA. This tip ... fragmentation. It is excellent for use with ... the inside diameter of the orifice is ...
... designed to optimize the accuracy and precision ... products is widely recognized by customers throughout ... extended over the years and now covers ... tips including filter tips, certified pure tips, ...
... plastic-wrapped racks of 96 tips, Sterilized Diamond- ... autoclave. Sterilized Diamond Tips are irradiated by ... delivered with a certificate of sterilization, specifying ... are certified free of detectable Rnase, Dnase, ...
Medicine Products: